Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: Targeting the renal tubule in diabetes

American Journal of Kidney Diseases

Volumn 64, Issue 1, 2014, Pages 16-24

  De Nicola, Luca ^a   Gabbai, Francis B ^b   Liberti, Maria Elena ^a   Sagliocca, Adelia ^a   Conte, Giuseppe ^a   Minutolo, Roberto ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

canagliflozin; dapagliflozin; Diabetes mellitus (DM); diabetic nephropathy (DN); glomerular filtration rate (GFR); hyperfiltration; Index Words; proximal tubule; SGLT2 inhibitor; sodium glucose cotransport; sodium glucose cotransporter 2 (SGLT2)

Indexed keywords

GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; KIDNEY HYPERTROPHY; KIDNEY TUBULE; KIDNEY TUBULE ABSORPTION; META ANALYSIS (TOPIC); NONHUMAN; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIABETES MELLITUS (DM); DIABETIC NEPHROPATHY (DN); GLOMERULAR FILTRATION RATE (GFR); HYPERFILTRATION; PROXIMAL TUBULE; SGLT2 INHIBITOR; SODIUM/GLUCOSE COTRANSPORT; SODIUM/GLUCOSE COTRANSPORTER 2 (SGLT2);

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY TUBULES, PROXIMAL; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84903266061     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.02.010     Document Type: Article

References (74)

1. L. Chen, D.J. Magliano, and P.Z. Zimmet The worldwide epidemiology of type 2 diabetes mellitus - present and future perspectives Nat Rev Endocrinol 8 4 2011 228 236
2. R.C. Atkins, and P. Zimmet Diabetic kidney disease: act now or pay later? Kidney Int 77 5 2010 375 377
3. L. De Nicola, P. Chiodini, and C. Zoccali et al. Prognosis of CKD patients receiving outpatient nephrology care in Italy Clin J Am Soc Nephrol 6 10 2011 2421 2428
4. F.C. Sasso, P. Chiodini, and O. Carbonara et al. High cardiovascular risk in patients with type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study Nephrol Dial Transplant 27 6 2012 2269 2274
5. P. Rossing, and D. de Zeeuw Need for better diabetes treatment for improved renal outcome Kidney Int Suppl 120 2011 S28 S32
6. V. Vallon, and R. Komers Pathophysiology of the diabetic kidney Compr Physiol 1 3 2011 1175 1232
7. S.C. Thomson, V. Vallon, and R.C. Blantz Kidney function in early diabetes: the tubular hypothesis of glomerular filtration Am J Physiol Renal Physiol 286 1 2004 F8 F15
8. Y.S. Kanwar, L. Sun, P. Xie, F.Y. Liu, and S. Chen A glimpse of various pathogenetic mechanism of diabetic nephropaty Annu Rev Pathol 6 2011 395 423
9. S.C. Thomson, and R.C. Blantz Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis J Am Soc Nephrol 19 12 2008 2272 2275
10. I.A. Miller Renal responses to sodium restriction in patients with early diabetes mellitus J Am Soc Nephrol 8 5 1997 749 755
11. C.M. Miracle, T. Rieg, H. Mansoury, V. Vallon, and S.C. Thomson Ornithine decarboxylase inhibitor eliminates hyperresponsiveness of the early diabetic proximal tubule to dietary salt Am J Physiol Renal Physiol 295 4 2008 F995 F1002
12. J. Ditzel, H.H. Lervang, and J. Brochner-Mortensen Renal sodium metabolism in relation to hypertension in diabetes Diabetes Metab 15 5, pt 2 1989 292 295
13. J.C. Mbanya, T.H. Thomas, R. Taylor, K.G. Alberti, and R. Wilkinson Increased proximal tubular sodium reabsorption in hypertensive patients with type 2 diabetes Diabet Med 6 7 1989 614 620
14. T.P. Hannedouche, A.G. Delgado, D.A. Gnionsahe, C. Boitard, B. Lacour, and J.P. Grunfeld Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes Kidney Int 37 4 1990 1126 1133
15. V. Vallon, K. Richter, R.C. Blantz, S. Thomson, and H. Osswald Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption J Am Soc Nephrol 10 12 1999 2569 2576
16. S.C. Thomson, A. Deng, D. Bao, J. Satriano, R.C. Blantz, and V. Vallon Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes J Clin Invest 107 2 2001 217 224
17. M. Pruijm, G. Wuerzner, and M. Maillard et al. Glomerular hyperfiltration and increased proximal sodium reabsorption in subjects with type 2 diabetes or impaired fasting glucose in a population of the African region Nephrol Dial Transplant 25 7 2010 2225 2231
18. S. Scholl-Bürgi, R. Santer, and J.H. Ehrich Long-term outcome of renal glucosuria type 0: the original patient and his natural history Nephrol Dial Transplant 19 9 2004 2394 2396
19. D.W. Barfuss, and J.A. Schafer Differences in active and passive glucose transport along the proximal nephron Am J Physiol 241 3 1981 F322 F332
20. Y.J. Lee, and H.J. Han Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells Kidney Int Suppl 106 2007 S27 S35
21. V. Vallon, K.A. Platt, and R. Cunard et al. SGLT2 mediates glucose reabsorption in the early proximal tubule J Am Soc Nephrol 22 1 2011 104 112
22. G.A. Quamme, and H.J. Freeman Evidence for a high-affinity sodium-dependent D-glucose transport system in the kidney Am J Physiol 253 1, pt 2 1987 F151 F157
23. C.E. Mogensen Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects Scand J Clin Lab Invest 28 1 1971 101 109
24. G.L. Bakris, V.A. Fonseca, and K. Sharma et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications Kidney Int 75 12 2009 1272 1277
25. H. Rahmoune, P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, and J. Brown Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 54 12 2005 3427 3434
26. V. Gorboulev, A. Schurmann, and V. Vallon et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion Diabetes 61 1 2012 187 196
27. T. Rieg, T. Masuda, and M. Gerasimova et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacologic SGLT2 inhibition in euglycemia Am J Physiol Renal Physiol 306 2 2014 F188 F193
28. D.R. Powell, C.M. DaCosta, and J. Gay et al. Improved glycemic control in mice lacking SGLT1 and SGLT2 Am J Physiol Endocrinol Metab 304 2 2013 E117 E130
29. V. Vallon The proximal tubule in the pathophysiology of the diabetic kidney Am J Physiol Regul Integr Comp Physiol 300 5 2011 1009 1022
30. V. Vallon, and S.C. Thomson Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney Annu Rev Physiol 74 2012 351 375
31. H.C. Huang, and P.A. Preisig G1 kinases and transforming growth factor-beta signaling are associated with a growth pattern switch in diabetes-induced renal growth Kidney Int 58 1 2000 162 172
32. J. Satriano, H. Mansoury, and A. Deng et al. Transition of kidney tubule cells to a senescent phenotype in early experimental diabetes Am J Physiol Cell Physiol 299 2010 374 380
33. H.J. Han, Y.J. Lee, S.H. Park, J.H. Lee, and M. Taub High glucose-induced oxidative stress inhibits Na/glucose cotransporter activity in renal proximal tubule cells Am J Physiol Renal Physiol 288 2005 F988 F996
34. T. Kuilman, C. Michaloglou, and L.C. Vredeveld et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network Cell 133 6 2008 1019 1031
35. D. Verzola, M.T. Gandolfo, and G. Gaetani et al. Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy Am J Physiol Renal Physiol 295 2008 F1563 F1573
36. G. Wolf, and F.N. Ziyadeh Molecular mechanisms of diabetic renal hypertrophy Kidney Int 56 2 1999 393 405
37. D. Feliers, and B.S. Kasinath Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells Mol Cell Endocrinol 314 1 2010 136 142
38. M. Bak, K. Thomsen, T. Christiansen, and A. Flyvbjerg Renal enlargement precedes renal hyperfiltration in early experimental diabetes in rats J Am Soc Nephrol 11 7 2000 1287 2192
39. S.B. Pedersen, A. Flyvbjerg, and B. Richelsen Inhibition of renal ornithine decarboxylase activity prevents kidney hypertrophy in experimental diabetes Am J Physiol Cell Physiol 264 2, pt 1 1993 C453 C456
40. K.D. Burns Angiotensin II and its receptors in the diabetic kidney Am J Kidney Dis 36 3 2000 449 467
41. E.J. Lewis, L.G. Hunsicker, W.R. Clarke for the Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 12 2001 851 860
42. B.M. Brenner, M.E. Cooper, D. de Zeeuw for the RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 2001 861 869
43. H.H. Parving, H. Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, P. Arner for the Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 12 2001 870 878
44. F.C. Sasso, O. Carbonara, and M. Persico et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension Diabetes Care 25 11 2002 1909 1913
45. L. De Nicola, R.C. Blantz, and F.B. Gabbai Renal functional reserve in the early stage of experimental diabetes Diabetes 41 3 1992 267 273
46. G.M. Magee, R.W. Bilous, C.R. Cardwell, S.J. Hunter, F. Kee, and D.G. Fogarty Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta analysis Diabetologia 52 4 2009 691 697
47. T. Moriya, A. Tsuchiya, S. Okizaki, A. Hayashi, K. Tanaka, and M. Schichiri Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo and microalbuminuric type 2 diabetes Kidney Int 81 5 2012 486 493
48. R.L. Chaiken, M. Eckert-Norton, and M. Bard et al. Hyperfiltration in African-American patients with type 2 diabetes. Cross-sectional and longitudinal data Diabetes Care 21 12 1998 2129 2134
49. R.G. Nelson, P.H. Bennet, G.J. Beck Diabetic Renal Disease Study Group Development and progression of renal disease in Prima Indians with non-insulin-dependent diabetes mellitus N Engl J Med 335 22 1996 1636 1642
50. P. Ruggenenti, E.L. Porrini, and F. Gaspari et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes Diabetes Care 35 10 2012 2061 2068
51. K.S. Kleinman, and L.G. Fine Prognostic implications of renal hypertrophy in diabetes mellitus Diabetes Metab Rev 4 2 1988 179 189
52. C.E. Mogensen, and M.J.F. Andersen Increased kidney size and glomerular filtration rate in early juvenile diabetes Diabetes 22 9 1973 706 712
53. C.E. Mogensen, and C.K. Christiansen Predicting diabetic nephropathy in insulin-dependent patients N Engl J Med 311 2 1984 89 93
54. G. Zerbini, R.N. Bonfanti, and F. Meschi et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes Diabetes 55 9 2006 2620 2625
55. V. Rigalleau, M. Garcia, and C. Lasseur et al. Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease BMC Nephrol 11 2010 3
56. C. Couchoud, and E. Villar End-stage renal disease epidemic in diabetics: is there light at the end of the tunnel? Nephrol Dial Transplant 28 5 2013 1073 1076
57. M.K. Ali, K.M. Bullard, J.B. Saaddine, C.C. Cowie, G. Imperatore, and E.W. Gregg Achievement of goals in U.S. diabetes care, 1999-2010 N Engl J Med 368 17 2013 1613 1624
58. R.R. Wing, P. Bolin, F.L. Brancati for the Look AHEAD Research Group Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes N Engl J Med 369 2 2013 145 154
59. E.S. Schellenberg, D.M. Dryden, B. Vandermeer, C. Ha, and C. Korownyk Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis Ann Intern Med 159 8 2013 543 551
60. M. Hanefeld, and T. Forst Dapagliflozin, an SGLT2 inhibitor, for diabetes Lancet 375 9733 2010 2196 2198
61. W.N. Washburn, and S.M. Poucher Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus Expert Opin Investig Drugs 22 4 2013 463 486
62. S.C. Thomson, T. Rieg, and C. Miracle et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat Am J Physiol Regul Integr Comp Physiol 302 1 2012 R75 R83
63. V. Vallon, M. Rose, and M. Gerasimova et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus Am J Physiol Renal Physiol 304 2 2013 F156 F167
64. V. Vallon, M. Gerasimova, and M. Rose et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice Am J Physiol Renal Physiol 306 2 2014 F194 F204
65. U. Panchapakesan, K. Pegg, and S. Gross et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells. Renoprotection in diabetic nephropathy? PLoS One 8 2 2013 e54442
66. R.A. Defronzo, M. Hompesch, and S. Kasichayanula et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes Diabetes Care 36 10 2013 3169 3176
67. H.J. Lambers Heerspink, D. de Zeeuw, L. Wie, B. Leslie, and J. List Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes Diabetes Obes Metab 15 9 2013 853 862
68. F. Gaspari, P. Ruggenenti, and E. Porrini et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics Kidney Int 84 1 2013 164 173
69. G. Musso, R. Gambino, M. Cassader, and G. Pagano A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials Ann Med 44 4 2012 375 393
70. D. Vasilakou, T. Karagiannis, and E. Athanasiadou et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis Ann Intern Med 159 4 2013 262 274
71. J.F. List, V. Woo, E. Morales, W. Tang, and F.T. Fiedorek Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 4 2009 650 657
72. J. Wilding, V. Woo, and N.G. Soler et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin Ann Intern Med 156 6 2012 405 415
73. W.T. Cefalu, L.A. Leiter, and K.H. Yoon et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 9896 2013 941 950
74. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control [published online ahead of print September 25, 2013]. Kidney Int. http://dx.doi.org/10. 1038/ki.2013.356.